GSK/Novartis Support For Benefiber Claims Too Thin To Convince NARB
This article was originally published in The Tan Sheet & The Rose Sheet
Referring to rather than providing two studies was GSK/Novartis' downfall in arguing before the National Advertising Review Board to support Benefiber regularity claims. GSK/Novartis questions the panel’s "refusal to accept the full translations of two confirmatory studies referred to in the record."
You may also be interested in...
To understand how Pepto-Bismol Ultra could be considered twice as strong as original as stated on packaging, consumers would need to "carefully review the Drug Facts on the back of both" products and "recognize that the active ingredient in both products is 525 mg of bismuth subsalicylate" but Ultra's dose is half original's.
Two months after referring advertising for its Hair Volume supplement to FTC, NAD zeroes in on claims for New Nordic USA's Skin Care Collagen Filler supplement. NAD says the firm should discontinue anti-wrinkle and collagen-building claims in the absence of reliable evidence from well-controlled human clinical testing.
Warning letters show FDA's coronavirus investigations inthe consumer health marketplace didn't stop when it suspended facility inspections. The letters identify firms that previously marketed only bedding products as offering supplements with coronavirus claims or that are in other countries and are shipping to US consumers products promoted with coronavirus claims.